At Rutgers Cancer Institute of New Jersey, scientific research goes beyond traditional microscopes and beakers. Our research members – whether basic scientists, bioinformatics specialists, statisticians, clinical specialists, population scientists, or others – have unique expertise in various translational aspects of cancer research. They work collaboratively to translate the latest innovations in cancer research into tomorrow’s treatments for cancer patients.
Current research in the Libutti Laboratory focuses on developing novel cancer therapies through an understanding of the tumor microenvironment by studying the interaction between tumor cells and the components of the tumor microenvironment. Dr. Libutti's work also focuses on a better understanding of the tumor suppressor genes MEN1 and FILIP1L.
Current research of the White Laboratory at Rutgers Cancer Institute of New Jersey has focused on translational research modulating the apoptosis pathway for cancer therapy and on the role of autophagy and cellular metabolism in cancer progression and treatment.
Dr. Elisa V. Bandera is an epidemiologist at Rutgers Cancer Institute of New Jersey and her research and training program focuses on the role of nutritional, hormonal, and other lifestyle factors play on cancer prevention and survival. She is also interested in early determinants of breast cancer risk.
Research in the Cao Lab focuses on epigenetic regulation of cancer immunity.
Dr. Chan’s lab is interested in understanding the role of p53 in cancer, and focuses on cancer genomics, cancer evolution and resistance to therapy, and gene regulation.
The goal of our lab is to fundamentally understand how cancer progresses within the unique microenvironment it creates. Specifically, we are interested in the hypoxic feature in tumor and how it enforces a selective pressure to generate the fittest or most aggressive clones.
The cancer genome informatics group, headed by Dr. Subhajyoti De, develops and applies novel genomics methods and computational toolsets to understand the hallmarks of cancer, and use that knowledge for better diagnosis, stratification, and treatment of this disease.
The Evens Laboratory studies complex cell-cell and signaling pathway connectivity interactions with the aim of improving lymphoma prognosis and treatment through: 1) development of new and innovative targeted cancer therapeutics, 2) investigation of biologic aspects of the immune system through novel microfluidic and single cell technology, and 3) discovery of "omic" biomarkers of efficacy and resistance to cancer therapeutics.
The Feng Laboratory studies the role of p53 in regulating cellular metabolism and how this contributes to tumor suppression. We are also interested in identifying new regulators and regulation mechanisms for p53 and its signaling pathway, and studying how mutant p53 can be targeted for cancer therapy. We also examine the mechanism of metabolic reprogramming in cancer and how metabolic changes in cancer can be targeted for therapy.
One of the goals of Dr. Foran's laboratory research is to develop a set of algorithms and software tools which facilitate automated imaging, analysis, and archiving of tumor tissue microarrays. In doing so, Dr. Foran's laboratory is currently working to determine the relationship between tumor image analysis-derived information and molecular status/clinical outcome in a way that will permit researchers to systematically carry out large-scale comparative analyses of human cancers.
The Ganesan Laboratory investigates the role of DNA repair defects in cancer, with a focus on how disruption of BRCA1-dependent DNA repair pathways affects normal DNA repair choice, and leads to both genomic instability and epigenetic instability.
The Gulhati lab is focused on basic and translational research in pancreatic cancer, a highly aggressive and lethal malignancy that will soon be the second leading cause of cancer death and remains remarkably resistant to all forms of therapy.
Research in the Guo Lab focuses on the field of cancer metabolism, with an emphasis on how autophagy is involved in modulating cancer metabolism to maintain Kras-driven lung tumor growth and metastasis.
The Gatza Laboratory leverages cancer genomics and bioinformatics with experimental molecular biology and genetics to identify and elucidate mechanisms of oncogenic signaling and cancer genesis as a means to further understand breast and ovarian tumor biology and to develop personalized cancer therapies.
Research in the Haffty laboratory at Rutgers Cancer Institute focuses on translational investigation of combining radiation therapies with novel drugs targeting breast cancer and other cancers.
The Herranz Lab aims to discover and define how oncogenic and tumor suppressor enhancers impact tumorigenesis in hematological and solid tumors, and to dissect the interplay between cancer cell-specific metabolic rewiring and epigenetics in T-cell Acute Lymphoblastic Leukemia (T-ALL).
Christian S. Hinrichs, MD, joins Rutgers Cancer Institute as Chief of the Section of Cancer Immunotherapy and Co-Director of the Duncan and Nancy MacMillan Cancer Immunology and Metabolism Center of Excellence. Dr. Hinrichs conducts basic research and clinical research to develop T-cell therapies for HPV-associated cancers and other epithelial malignancies.
The research interest of Dr. Hu's laboratory is to understand the alteration of important cancer-related signaling pathways in tumorigenesis, including the p53 and LIF signaling.
The Khiabanian Laboratory develops mathematical methods and employs high-throughput genomics techniques to understand the underlying genetics of human malignancies and the molecular epidemiology of disease-causing organisms, especially to study the evolution of clonal expansions in the context of disease transformation and relapse.
The research interests of Dr. Kim's laboratory focus on uncovering molecular mechanisms that govern sensitivity and resistance to anti-androgen therapy in prostate cancer and renal cell carcinoma.
The focus of the Lattime Lab lies in the interrogation of the tumor-host immune interaction both systemic and in the tumor microenvironmemnt and, based on preclinical models, the development and testing of novel immunotherapeutic modalities in early phase clinical trials.
Research in our lab largely focuses on elucidating the molecular mechanisms that underlie the pathogenesis of cancer-predisposition syndromes and hematological malignancies. In particular, we are exploring the contribution of defective replication, transcription and repair to genomic instability in disorders like Fanconi anemia and Adult T-cell leukemia/lymphoma.
The Pine lab focuses on stem cell signaling pathways that drive lung carcinogenesis, lung tumor progression, and resistance to therapy.
Led by Dr. Hatem Sabaawy, investigators at the Cancer Institute's zebrafish laboratory use zebrafish models to map the common genetic defects in cancer, identify new small molecules for targeted treatment, and predict each cancer patient's response to therapy in precision medicine trials. Among other applications, learn how zebrafish research is helping in the fight against prostate cancer.
Current research of the Shen Laboratory focuses the mechanisms by which genomic instability is provoked during tumorigenesis. Using a BRCA2 interacting protein BCCIP and its associated protein network as the platform, we investigate the roles of mammalian homologous recombination (HR) in error-less DNA repair, replication fidelity, and precise mitotic cell division.
Research in the Bing Xia Laboratory is focused on the roles of DNA damage, oxidative stress and autophagy in cancer development. Much of our research program originated from our discovery of the PALB2 tumor suppressor, which functionally links BRCA1 and BRCA2, the two major breast cancer suppressor proteins in the DNA damage response.
The Zheng Laboratory is interested in the mechanisms of nutrient signaling that control growth and metabolism, their contributions to cancer and diseases such as diabetes and hepatic steatosis, and development of novel therapeutic strategies.
The research at the Center for Systems and Computational Biology focuses on cancer genomics and translational medicine, particularly developing novel quantitative and experimental approaches to discover disease-driving aberrations, understand cancer pathogenesis, improve diagnosis, and design effective clinical trials and precise treatment strategies for patients under active care.